Literature DB >> 23256815

Medicinal potential of ciprofloxacin and its derivatives.

William Castro1, Maribel Navarro, Christophe Biot.   

Abstract

Ciprofloxacin (CP) is a fluoroquinolone that is highly active against diverse microorganisms. At concentrations less than 1 µg/ml it is active against a diverse types of bacteria, including Staphylococcus aureus, Staphylococcus epidermidis, Bacillius subtilius, Escherichia coli and Mycobacterium tuberculosis. In addition, it has shown to be effective against other diseases such as malaria, cancer and AIDS. The extended antimicrobial activity, lack of plasmid-mediated resistance, large volume of distribution and minimal adverse effects of CP are therapeutically advantageous. In the pursuit of increasing their effectiveness against these diseases and prevent unwanted resistance, researchers have begun to synthesize a class of organic, inorganic and organometallic derivatives, which have displayed interesting activities. This review describes the development and recent advances on the evaluation of CP and its derivatives as a new class of drugs with potential for clinical development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23256815     DOI: 10.4155/fmc.12.181

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  13 in total

1.  New 7-piperazinylquinolones containing (benzo[d]imidazol-2-yl)methyl moiety as potent antibacterial agents.

Authors:  Hojat-Allah Arab; Mohammad Ali Faramarzi; Nasrin Samadi; Hamid Irannejad; Alireza Foroumadi; Saeed Emami
Journal:  Mol Divers       Date:  2018-06-07       Impact factor: 2.943

2.  Design and synthesis of theranostic antibiotic nanodrugs that display enhanced antibacterial activity and luminescence.

Authors:  Sheng Xie; Sesha Manuguri; Giampiero Proietti; Joakim Romson; Ying Fu; A Ken Inge; Bin Wu; Yang Zhang; Daniel Häll; Olof Ramström; Mingdi Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-25       Impact factor: 11.205

3.  Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin-Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity.

Authors:  Wilma Neumann; Martina Sassone-Corsi; Manuela Raffatellu; Elizabeth M Nolan
Journal:  J Am Chem Soc       Date:  2018-04-10       Impact factor: 15.419

4.  Design and Synthesis of Menthol and Thymol Derived Ciprofloxacin: Influence of Structural Modifications on the Antibacterial Activity and Anticancer Properties.

Authors:  Tomasz Szostek; Daniel Szulczyk; Jolanta Szymańska-Majchrzak; Michał Koliński; Sebastian Kmiecik; Dagmara Otto-Ślusarczyk; Aleksandra Zawodnik; Eliza Rajkowska; Kinga Chaniewicz; Marta Struga; Piotr Roszkowski
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

5.  Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.

Authors:  Jonathan H Boyce; Bobo Dang; Beatrice Ary; Quinn Edmondson; Charles S Craik; William F DeGrado; Ian B Seiple
Journal:  J Am Chem Soc       Date:  2020-12-10       Impact factor: 15.419

6.  Complete Degradation and Detoxification of Ciprofloxacin by a Micro-/Nanostructured Biogenic Mn Oxide Composite from a Highly Active Mn2+-Oxidizing Pseudomonas Strain.

Authors:  Li Li; Jin Liu; Jie Zeng; Jiaoqing Li; Yongxuan Liu; Xiaowen Sun; Liangzheng Xu; Lin Li
Journal:  Nanomaterials (Basel)       Date:  2021-06-24       Impact factor: 5.076

7.  Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors.

Authors:  Majed M Masadeh; Karem H Alzoubi; Omar F Khabour; Sayer I Al-Azzam
Journal:  Curr Ther Res Clin Exp       Date:  2014-12-05

8.  SILVER NANOPARTICLES-DISK DIFFUSION TEST AGAINST Escherichia coli ISOLATES.

Authors:  Francisco Afrânio Cunha; Kamila Rocha Maia; Eduardo José Jucá Mallman; Maria da Conceição Dos Santos Oliveira Cunha; Antonio Auberson Martins Maciel; Ieda Pereira de Souza; Everardo Albuquerque Menezes; Pierre Basílio Almeida Fechine
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-09-22       Impact factor: 1.846

9.  Increased expression of Qnr is sufficient to confer clinical resistance to ciprofloxacin in Escherichia coli.

Authors:  Linnéa Garoff; Kavita Yadav; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

10.  Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli.

Authors:  Lisa Praski Alzrigat; Douglas L Huseby; Gerrit Brandis; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.